Cabotegravir and Rilpivirine Concentrations and HIV-1 RNA Suppression in Genital Fluids and Rectum in People with HIV on Long-Acting Intramuscular Cabotegravir Plus Rilpivirine Antiretroviral Therapy

This study examined cabotegravir (CAB) and rilpivirine (RPV) distribution and HIV suppression in genital and rectal compartments after switching to long-acting intramuscular CAB + RPV administered every two months. At month 4, drug concentrations were measured in blood plasma, seminal plasma (SP), rectal tissue (RT), and cervicovaginal fluid (CVF). Thirty-one participants (16 cisgender men, 15 cisgender women) were included. CAB and RPV exhibited different distributions between compartments. Unbound CAB exceeded the EC50 in SP, RT and CVF while unbound RPV exceeded the EC50 in RT and CVF but not in SP. All participants maintained HIV-1 RNA <20 copies/mL in all matrices. Clinical Trial Registration: EudraCT Number: 2021-006779-41.

Authors

Institutions

Publication Details

Journal
The Journal of Infectious Diseases
Published
2025-10-29
DOI
https://doi.org/10.1093/infdis/jiaf551
Citations
1
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
1.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cabotegravir and Rilpivirine Concentrations and HIV-1 RNA Suppression in Genital Fluids and Rectum in People with HIV on Long-Acting Intramuscular Cabotegravir Plus Rilpivirine Antiretroviral Therapy

Benito García, Irene Soriano, Sandra Morenilla, María Saumoy et al.
1 citations
The Journal of Infectious Diseases
HIV/AIDS drug development and treatment
1.40
article

Cabotegravir and Rilpivirine Concentrations and HIV-1 RNA Suppression in Genital Fluids and Rectum in People with HIV on Long-Acting Intramuscular Cabotegravir Plus Rilpivirine Antiretroviral Therapy

Benito García, Irene Soriano, Sandra Morenilla, María Saumoy, Amanda P. Schauer, Sofía Scévola, Juan Tiraboschi, Craig Sykes, Arkaitz Imaz, Jordí Niubó, Alicia Sedó, Mackenzie Leigh Cottrell, Camila Piatti, Analuz Fernández, Dahyr Olivas Medina, Júlia Guevara-Figueras
article en
1 citations

Abstract

This study examined cabotegravir (CAB) and rilpivirine (RPV) distribution and HIV suppression in genital and rectal compartments after switching to long-acting intramuscular CAB + RPV administered every two months. At month 4, drug concentrations were measured in blood plasma, seminal plasma (SP), rectal tissue (RT), and cervicovaginal fluid (CVF). Thirty-one participants (16 cisgender men, 15 cisgender women) were included. CAB and RPV exhibited different distributions between compartments. Unbound CAB exceeded the EC50 in SP, RT and CVF while unbound RPV exceeded the EC50 in RT and CVF but not in SP. All participants maintained HIV-1 RNA <20 copies/mL in all matrices. Clinical Trial Registration: EudraCT Number: 2021-006779-41.

The Journal of Infectious DiseasesVol. 233(2)
University of North Carolina at Chapel Hill (US), Instituto de Salud Carlos III (ES), Bellvitge University Hospital (ES), Institut d'Investigació Biomédica de Bellvitge (ES), Centro de Investigación Biomédica en Red (ES), Universitat de Barcelona (ES)
Openalex Percentile: Top 15%
HIV/AIDS drug development and treatment
1.40
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.